Effect of apomorphine on cognitive performance and sensorimotor gating in humans

Department of Psychiatry, Radboud Medical Centre Nijmegen, 6500 HB Nijmegen, The Netherlands.
Psychopharmacology (Impact Factor: 3.88). 10/2009; 207(4):559-69. DOI: 10.1007/s00213-009-1686-1
Source: PubMed


Dysfunction of brain dopamine systems is involved in various neuropsychiatric disorders. Challenge studies with dopamine receptor agonists have been performed to assess dopamine receptor functioning, classically using the release of growth hormone (GH) from the hindbrain as primary outcome measure. The objective of the current study was to assess dopamine receptor functioning at the forebrain level.
Fifteen healthy male volunteers received apomorphine sublingually (2 mg), subcutaneously (0.005 mg/kg), and placebo in a balanced, double-blind, cross-over design. Outcome measures were plasma GH levels, performance on an AX continuous performance test, and prepulse inhibition of the acoustic startle. The relation between central outcome measures and apomorphine levels observed in plasma and calculated in the brain was modeled using a two-compartmental pharmacokinetic-pharmacodynamic analysis.
After administration of apomorphine, plasma GH increased and performance on the AX continuous performance test deteriorated, particularly in participants with low baseline performance. Apomorphine disrupted prepulse inhibition (PPI) on high-intensity (85 dB) prepulse trials and improved PPI on low intensity (75 dB) prepulse trials, particularly in participants with low baseline PPI. High cognitive performance at baseline was associated with reduced baseline sensorimotor gating. Neurophysiological measures correlated best with calculated brain apomorphine levels after subcutaneous administration.
The apomorphine challenge test appears a useful tool to assess dopamine receptor functioning at the forebrain level. Modulation of the effect of apomorphine by baseline performance levels may be explained by an inverted U-shape relation between prefrontal dopamine functioning and cognitive performance, and mesolimbic dopamine functioning and sensorimotor gating. Future apomorphine challenge tests preferentially use multiple outcome measures, after subcutaneous administration of apomorphine.

Download full-text


Available from: Arnt F A Schellekens,
  • Source
    • "Some of these studies specifically investigate the dopaminergic system in the prefrontal cortex (PFC) (Zavitsanou et al., 1999) or in the striatum (Swerdlow et al., 2007), showing that the DA system in both the PFC and the striatum might be involved in PPI modulation. Similarly, in healthy humans, there is support for modulation of PPI by substances influencing DA metabolism or transmission , or DA receptor agonists/antagonists, but results have been inconclusive (Bitsios et al., 2005; Giakoumaki et al., 2008; Roussos et al., 2009b; Schellekens et al., 2010; Swerdlow et al., 2002; Swerdlow et al., 2003). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Reduced prepulse inhibition (PPI) of the acoustic startle response is thought to represent a robust biomarker in schizophrenia. Reduced PPI has been demonstrated in subjects at ultra high risk (UHR) for developing psychosis. Imaging studies report disruption of striatal dopaminergic neurotransmission in patients with schizophrenia. First, we compared the PPI of the acoustic startle response in UHR subjects versus healthy controls, to see if we could replicate previous findings of reduced PPI; secondly, we investigated our hypothesis that PPI would be negatively correlated with striatal synaptic dopamine (DA) concentration. We measured the startle reactivity and PPI of the acoustic startle response in 14 UHR subjects, and 14 age- and gender-matched healthy controls. Imaging of 11 UHR subjects and 11 healthy controls was completed by an [(123)I]-IBZM (radiotracer for dopamine D2/3 receptors) SPECT, at baseline and again after DA depletion with alpha-methyl-para-tyrosine (AMPT). The percentage change in striatal [(123)I]-IBZM radiotracer binding potential is a proxy of striatal synaptic DA concentration. UHR subjects showed reduced PPI, compared to control subjects. In both UHR and control subjects, there were no significant correlations between striatal synaptic DA concentration and PPI. We provide further evidence for the hypothesis that these two biomarkers are measuring different aspects of pathophysiology.
    Journal of Psychopharmacology 02/2014; 28(6). DOI:10.1177/0269881113519507 · 3.59 Impact Factor
  • Source
    • "Nevertheless, 11 participants reported nausea and somnolence after administration of apomorphine. Consistent with existing work employing this combination of drugs [52], [55], these side effects were short-lived, generally lasting no more than 15 minutes, and participants reported being alert and task-ready after this interval. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite much research, it remains unclear if dopamine is directly involved in novelty detection or plays a role in orchestrating the subsequent cognitive response. This ambiguity stems in part from a reliance on experimental designs where novelty is manipulated and dopaminergic activity is subsequently observed. Here we adopt the alternative approach: we manipulate dopamine activity using apomorphine (D1/D2 agonist) and measure the change in neurological indices of novelty processing. In separate drug and placebo sessions, participants completed a von Restorff task. Apomorphine speeded and potentiated the novelty-elicited N2, an Event-Related Potential (ERP) component thought to index early aspects of novelty detection, and caused novel-font words to be better recalled. Apomorphine also decreased the amplitude of the novelty-P3a. An increase in D1/D2 receptor activation thus appears to potentiate neural sensitivity to novel stimuli, causing this content to be better encoded.
    PLoS ONE 06/2013; 8(6):e66469. DOI:10.1371/journal.pone.0066469 · 3.23 Impact Factor
  • Source
    • "Apomorphine is a nonselective dopamine agonist, although it exhibits a very high affinity for the D2 receptor family, and particularly the D4 receptor (Millan et al. 2002). At low doses (i.e., ~0.004 mg/kg), apomorphine reduces the dopamine release within the striatum via the inhibitory D2 receptors located presynaptically (i.e., on the nigrostriatal terminals) (Montoya et al. 2008; Schellekens et al. 2010). In contrast, at the higher (10-fold) doses used for PD treatment (i.e., ~0.04 mg/kg), apomorphine mainly stimulates the postsynaptic D2 receptors expressed by striatal neurons (Bowron 2004; LeWitt 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dopaminergic therapy in Parkinson's disease (PD) can improve some cognitive functions while worsening others. These opposite effects might reflect different levels of residual dopamine in distinct parts of the striatum, although the underlying mechanisms remain poorly understood. We used functional magnetic resonance imaging (fMRI) to address how apomorphine, a potent dopamine agonist, influences brain activity associated with working memory in PD patients with variable levels of nigrostriatal degeneration, as assessed via dopamine-transporter (DAT) scan. Twelve PD patients underwent two fMRI sessions (Off-, On-apomorphine) and one DAT-scan session. Twelve sex-, age-, and education-matched healthy controls underwent one fMRI session. The core fMRI analyses explored: (1) the main effect of group; (2) the main effect of treatment; and (3) linear and nonlinear interactions between treatment and DAT levels. Relative to controls, PD-Off patients showed greater activations within posterior attentional regions (e.g., precuneus). PD-On versus PD-Off patients displayed reduced left superior frontal gyrus activation and enhanced striatal activation during working-memory task. The relation between DAT levels and striatal responses to apomorphine followed an inverted-U-shaped model (i.e., the apomorphine effect on striatal activity in PD patients with intermediate DAT levels was opposite to that observed in PD patients with higher and lower DAT levels). Previous research in PD demonstrated that the nigrostriatal degeneration (tracked via DAT scan) is associated with inverted-U-shaped rearrangements of postsynaptic D2-receptors sensitivity. Hence, it can be hypothesized that individual differences in DAT levels drove striatal responses to apomorphine via D2-receptor-mediated mechanisms.
    Brain and Behavior 05/2013; 3(3):249-62. DOI:10.1002/brb3.115 · 2.24 Impact Factor
Show more